Characteristics and Treatment Response of Patients with HIV Associated Kaposi's Sarcoma in Central Kenya

被引:1
|
作者
McLigeyo, Angela [1 ]
Owuor, Kevin [1 ]
Ng'ang'a, Evelyne [1 ]
Mwangi, Jonathan [2 ]
Wekesa, Paul [1 ]
机构
[1] Ctr Hlth Solut Kenya, CVS Plaza,4th Floor,Kasuku Rd,Off Lenana Rd, Nairobi, Kenya
[2] Ctr Dis Control & Prevent CDC, Div Global HIV & TB, Nairobi, Kenya
来源
HIV AIDS-RESEARCH AND PALLIATIVE CARE | 2022年 / 14卷
关键词
HIV; Kaposi's sarcoma; characteristics; treatment; response; adults; ACTIVE ANTIRETROVIRAL THERAPY; INFECTED INDIVIDUALS; HERPESVIRUS; MEN; HUMAN-HERPESVIRUS-8; PREVALENCE; OUTCOMES; PATTERN; CANCER; HAART;
D O I
10.2147/HIV.S359278
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Kaposi's sarcoma (KS) is the most common HIV-associated malignancy in Sub Saharan Africa. In 2018, it was the 7th most common cancer and the 10th most common cause of cancer death in Kenya. This study aimed to describe the baseline and clinical characteristics and treatment response observed following combined antiretroviral treatment (ART) and chemotherapy in KS patients. Methods: This was a descriptive analysis of patients aged >= 15 years treated for KS and HIV at 11 treatment hubs in Central Kenya between 2011 and 2014. Data on baseline and clinical characteristics, ART and chemotherapy regimens as well as treatment responses were collected from patient files and KS registers. Results: A total of 95 patients presenting with clinically suspected KS with no history of prior treatment with chemotherapy were reviewed. All had histological diagnostic samples taken with 67 (71%) having confirmed KS. All were on ART, either newly initiated or continuing on ART, and 63 of the 67 (94.0%) confirmed to have KS received chemotherapy. Among the 67 patients with confirmed KS, mean age was 37.2 years (+/- 13.2) and 40 (59.7%) were male. More than 80% had normal baseline and follow-up BMI, and 34 (50.7%) were on a TDF-based regimen, 52 (77.6%) were treated with the Adriamycin, bleomycin and vinblastine protocol, and 55 (82.1%) had KS diagnosis before HIV diagnosis. All 67 patients had mucocutaneous lesions. Complete, partial response and stable disease occurred in 27 (40.3%), 10 (14.9%) and 7 (10.4%), respectively, 11 (16.4%) defaulted care during treatment, six patients died during treatment, four patients died before treatment while two patients had progressive disease during chemotherapy. Conclusion: The diagnosis of KS preceded HIV in the majority of cases reviewed, with histology helpful to reduce misdiagnosis. Patients generally complied with their chemotherapy, with overall good response rate for this intervention implemented at primary health-care facilities.
引用
收藏
页码:207 / 215
页数:9
相关论文
共 50 条
  • [1] Telling the story of intersectional stigma in HIV-associated Kaposi's sarcoma in western Kenya: a convergent mixed-methods approach
    Collier, Sigrid
    Singh, Rhea
    Semeere, Aggrey
    Byakwaga, Helen
    Laker-Oketta, Miriam
    McMahon, Devon E.
    Chemtai, Linda
    Grant, Merridy
    Butler, Lisa
    Bogart, Laura
    Bassett, Ingrid, V
    Kiprono, Samson
    Maurer, Toby
    Martin, Jeffrey
    Busakhala, Naftali
    Freeman, Esther E.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25
  • [2] Barriers and facilitators to chemotherapy initiation and adherence for patients with HIV-associated Kaposi's sarcoma in Kenya: a qualitative study
    McMahon, Devon E.
    Singh, Rhea
    Chemtai, Linda
    Semeere, Aggrey
    Byakwaga, Helen
    Grant, Merridy
    Laker-Oketta, Miriam
    Lagat, Celestine
    Collier, Sigrid
    Maurer, Toby
    Martin, Jeffrey
    Bassett, Ingrid V.
    Butler, Lisa
    Kiprono, Samson
    Busakhala, Naftali
    Freeman, Esther E.
    INFECTIOUS AGENTS AND CANCER, 2022, 17 (01)
  • [3] HIV-Associated Kaposi's Sarcoma
    Hoffmann, Christian
    Sabranski, Michael
    Esser, Stefan
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (03) : 94 - 98
  • [4] Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi's Sarcoma Patients
    Lidenge, Salum J.
    Tso, For Yue
    Mortazavi, Yasaman
    Ngowi, John R.
    Shea, Danielle M.
    Mwaiselage, Julius
    Wood, Charles
    West, John T.
    CANCERS, 2020, 12 (06) : 1 - 15
  • [5] HIV-Associated Cutaneous Kaposi's Sarcoma
    Alluhaybi, Abdulrahman F.
    Hatatah, Nael M.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (02)
  • [6] Oral HIV-associated Kaposi sarcoma
    Pantanowitz, L.
    Khammissa, R. A. G.
    Lemmer, J.
    Feller, L.
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2013, 42 (03) : 201 - 207
  • [7] Kaposi's sarcoma-associated herpesvirus protein ORF75 among HIV-1 patients in Kenya
    Demba, Rodgers N.
    Aradi, Sylviah M.
    Mwau, Matilu
    Mwanda, Walter O.
    AFRICAN JOURNAL OF LABORATORY MEDICINE, 2020, 9 (01)
  • [8] Mortality disparities among patients with HIV-associated Kaposi's sarcoma in the southern United States
    Knights, Sheena M.
    Lazarte, Susana M.
    Kainthla, Radhika
    Chiao, Elizabeth Y.
    Nijhawan, Ank E.
    AIDS, 2022, 36 (05) : 721 - 728
  • [9] Evaluation of clinical course, histopathological and treatment characteristics of patients with Kaposi's sarcoma
    Polat, Asude Kara
    Karaali, Muge Gore
    Aksu, Ayse Esra Koku
    Eblebici, Cem
    Gurel, Mehmet Salih
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2018, 52 (04): : 131 - 136
  • [10] Therapeutic Perspectives in the Systemic Treatment of Kaposi's Sarcoma
    Valantin, Marc-Antoine
    Royston, Lena
    Hentzien, Maxime
    Jary, Aude
    Makinson, Alain
    Veyri, Marianne
    Ronot-Bregigeon, Sylvie
    Isnard, Stephane
    Palich, Romain
    Routy, Jean-Pierre
    CANCERS, 2022, 14 (03)